In this article, we will explore the topic of AgeX Therapeutics from a broad and multidisciplinary perspective. AgeX Therapeutics is a topic that has sparked interest and debate in various areas of society, from politics to popular culture. Throughout history, AgeX Therapeutics has played a crucial role in shaping our social, economic and cultural reality. Through this analysis, we will seek to understand the complexities and dimensions of AgeX Therapeutics, as well as its impact on our lives. From its origins to its current relevance, this article will delve into the different facets of AgeX Therapeutics and how it has shaped the world we inhabit.
| Company type | Public |
|---|---|
| AMEX: AGE | |
| Industry | Biotechnology, aging research |
| Founded | 2017 |
| Founder | Michael D. West |
| Headquarters | Alameda, California |
Key people | Michael D. West (CEO) Gregory Bailey (chairman) |
| Website | www |
AgeX Therapeutics, Inc. (commonly abbreviated as AgeX Therapeutics or simply AgeX) is an American biotechnology company developing medical therapeutics related to human longevity. It was founded in 2017 by Michael D. West, initially as a subsidiary of BioTime, Inc. with backing from British billionaire investor Jim Mellon and others.
The chairman is Gregory Bailey, who was an early backer and board member of Medivation until its acquisition by Pfizer in 2016 for $14 billion.
In January 2020, AgeX Therapeutics announced a research collaboration with a Japanese biopharma company utilizing AgeX's UniverCyte technology platform.